CIT-013 not checked

Citryll BV

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total · 3 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Hidradenitis Suppurativa (HS)
Main trialPhase 2
“The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS. Participants will: Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks…”In the company’s words, NCT06993233 on ClinicalTrials.gov

Other drugs for Hidradenitis Suppurativa (HS)

All 29 drugs for Hidradenitis Suppurativa (HS)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Apr 2027 A Study With CIT-013 in HS Patients
Phase 2Completed 2 Jul 2026 A Study With CIT-013 in RA Patients
Phase 1Completed 10 Aug 2026 Trial in Healthy Volunteers to Evaluate 150 mg Subcutaneous CIT-013
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow CIT-013

Following is part of Solo: you see every change to CIT-013 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in